AIM vs INBS

AIM ImmunoTech exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a Current Ratio of 0.53, indicating a looming liquidity crisis. The company has suffered a catastrophic price collapse, falling from a 52-week high of $19.74 to $0.52, reflecting a near-total loss of investor confidence. While one analyst maintains a 'strong_buy' rating with a $10 target, this is completely decoupled from the fundamental reality of -53.3% revenue growth and an operating margin of -14,057%. The combination of negative growth, extreme valuation (P/S of 48.15), and failing health metrics suggests a high probability of insolvency or massive dilution.

The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.